Zobrazeno 1 - 10
of 159
pro vyhledávání: '"QuChang Ouyang"'
Autor:
Binliang Liu, Zhe‐Yu Hu, Ning Xie, Liping Liu, Jing Li, Xiaohong Yang, Huawu Xiao, Xuran Zhao, Can Tian, Hui Wu, Jun Lu, Jianxiang Gao, Xuming Hu, Min Cao, Zhengrong Shui, Yu Tang, Quchang Ouyang
Publikováno v:
Cancer Innovation, Vol 3, Iss 6, Pp n/a-n/a (2024)
Abstract Background CDK4/6 inhibitors (CDK4/6i) have shown promising results in the treatment of hormone receptor‐positive (HR+) metastatic breast cancer (MBC) when combined with endocrine therapy (ET). It is crucial to evaluate the actual effectiv
Externí odkaz:
https://doaj.org/article/13b880c7b9a24ee4801deeb38308ad66
Autor:
Zhe-Yu Hu, Binliang Liu, Ning Xie, Xiaohong Yang, Liping Liu, Huawu Xiao, Jing Li, Hui Wu, Jianxiang Gao, Jun Lu, Xuming Hu, Min Cao, Zhengrong Shui, Can Tian, Quchang Ouyang
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Aims This investigation aims to elucidate the treatment status of advanced HR+/HER2- breast cancer patients in Hunan Province of Central Southern China from November 2021 to December 2022. Methods Data from 301 patients with advanced HR+/HER
Externí odkaz:
https://doaj.org/article/e9c30214395a45e9b2c6da56ab5e2a2c
Autor:
Qingyuan Zhang, Kunwei Shen, Chuan-gui Song, Quchang Ouyang, Zhenzhen Liu, Qiang Liu, Jifeng Feng, Joanne W. Y. Chiu, Jinhai Tang, Zefei Jiang, Ling-Ming Tseng, Xiaojia Wang, Liu Yang, Chenxi Qian, Zhimin Shao
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Abemaciclib was the first cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved globally in the adjuvant setting for high-risk hormone-receptor positive (HR+)/human epidermal growth factor 2 negative (HER2−) early breast cancer (EBC),
Externí odkaz:
https://doaj.org/article/333eb24b4ee049a89b802c1cd1b250f2
Autor:
Min Yan, Quchang Ouyang, Tao Sun, Limin Niu, Jin Yang, Li Li, Yuhua Song, Chunfang Hao, Zhanhong Chen, Zhenzhen Liu, Huimin Lv, Mengwei Zhang, Liping Liu, Xiaohong Yang, Huawu Xiao, Zhichao Gao, Xiaorui Li, Fangyuan Dong, Lingxiao Zhang, Danfeng Dong, Xiuchun Chen, Jianghua Qiao, Guifang Zhang, Huiai Zeng, Jing Wang, Huihui Sun, Yajing Feng, Yuting Chen, Fangzhou Xia
Publikováno v:
EClinicalMedicine, Vol 76, Iss , Pp 102837- (2024)
Summary: Background: The phase 2 PERMEATE study has shown the antitumor activity and safety of pyrotinib plus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and brain metastases. In thi
Externí odkaz:
https://doaj.org/article/966841c960ef41acbe90d6ecf940b5ac
Autor:
Qiao Li, Jiaxuan Liu, Qingyuan Zhang, Quchang Ouyang, Yang Zhang, Qiang Liu, Tao Sun, Feng Ye, Baochun Zhang, Summer Xia, Bangyong Zhang, Binghe Xu
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-9 (2024)
Abstract This multicenter, phase II study (NCT03872791) aims to evaluate the efficacy and safety of the anti-PD-L1/CTLA-4 bispecific antibody KN046 combined with nab-paclitaxel in the first-line treatment of patients with metastatic triple-negative b
Externí odkaz:
https://doaj.org/article/b981f4a864714addbb58aef5a7a28913
Autor:
Quchang Ouyang, Ying Wang, Jian Zhang, Qiong Wu, Hongying Wei, Chuan Li, Xiaoling Qian, Xichun Hu
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 21849-21860 (2023)
Abstract Background Approximately 40% of patients with hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐negative advanced breast cancer (ABC) exhibit PIK3CA mutations. Aims This study aims to evaluate the safety,
Externí odkaz:
https://doaj.org/article/f29f5501c77c420596ac318b4e91bbe0
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-10 (2023)
Abstract In our phase Ib trial (ClinialTrials.gov Identifier: NCT03855358), benmelstobart (TQB2450), a novel humanized IgG1 antibody against PD-L1, plus antiangiogenic multikinase inhibitor, anlotinib, demonstrated promising antitumor activities in p
Externí odkaz:
https://doaj.org/article/ac7e087fb5b843f28fe6dfd55d12279e
Autor:
Jun Cao, Yuee Teng, Huiping Li, Lili Zhang, Quchang Ouyang, Weimin Xie, Yueyin Pan, Zhenchuan Song, Xiaoling Ling, Xiaohong Wu, Jingwei Xu, Li Li, Liping Ren, Hong Wang, Dongxian Zhou, Jing Luo, Xichun Hu
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-10 (2023)
Abstract Background Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer and primary resistance to trastuzumab have a poor clinical outcome and lack good evidence to inform clinical decision. This study invest
Externí odkaz:
https://doaj.org/article/bdb8e110b7b14f79b5c021294f404095
Autor:
Zhe-Yu Hu, Min Yan, Huihua Xiong, Li Ran, Jincai Zhong, Ting Luo, Tao Sun, Ning Xie, Liping Liu, Xiaohong Yang, Huawu Xiao, Jing Li, Binliang Liu, Quchang Ouyang
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-10 (2023)
Abstract Background Human epidermal growth factor receptor 2 (HER2) targeted therapy combined with endocrine therapy has been recommended as an alternative treatment strategy for patients with hormone receptor (HR)-positive, HER2-positive metastatic
Externí odkaz:
https://doaj.org/article/945eca1f6a834632920aa7e7321a30fe
Autor:
Binghe Xu, Qingyuan Zhang, Xichun Hu, Qing Li, Tao Sun, Wei Li, Quchang Ouyang, Jingfen Wang, Zhongsheng Tong, Min Yan, Huiping Li, Xiaohua Zeng, Changping Shan, Xian Wang, Xi Yan, Jian Zhang, Yue Zhang, Jiani Wang, Liang Zhang, Ying Lin, Jifeng Feng, Qianjun Chen, Jian Huang, Lu Zhang, Lisong Yang, Ying Tian, Hongyan Shang
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 13, Iss 5, Pp 2250-2258 (2023)
Entinostat plus exemestane in hormone receptor-positive (HR+) advanced breast cancer (ABC) previously showed encouraging outcomes. This multicenter phase 3 trial evaluated the efficacy and safety of entinostat plus exemestane in Chinese patients with
Externí odkaz:
https://doaj.org/article/29416e726eef485fb5be6cf4325c42c0